Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+metastatic breast cancer

被引：0
|
作者：
Gajria, D. [1 ]
King, T. [1 ]
Pannu, H. [1 ]
Sakr, R. [1 ]
Modi, S. [1 ]
Drullinsky, P. [1 ]
Syldor, A. [1 ]
Path, S. [1 ]
Seidman, A. [1 ]
Norton, L. [1 ]
Rosen, N. [1 ]
Hudis, C. [1 ]
Chandarlapaty, S. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P5-18-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-04
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer
    Niculescu-Duvaz, Ion
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (03) : 350 - 360
  • [33] Trastuzumab and vinorelbine or taxane chemotherapy for HER2+metastatic breast cancer: The TRAVIOTA study.
    Burstein, H. J.
    Keshaviah, A.
    Baron, A.
    Hart, R.
    Lambert-Falls, R.
    Marcom, P. K.
    Gelman, R.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 40S - 40S
  • [34] Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer
    Rigakos, Georgios
    Razis, Evangelia
    Koliou, Georgia-Angeliki
    Oikonomopoulos, Georgios
    Tsolaki, Eleftheria
    Sperinde, Jeff
    Chrisafi, Sofia
    Zarkavelis, George
    Pazarli, Elissavet
    Batistatou, Anna
    Kourea, Helen P.
    Papakostas, Pavlos
    Bafaloukos, Dimitrios
    Asimakopoulou, Natalia, I
    Res, Eleni
    Kotsakis, Athanasios
    Pectasides, Dimitrios
    Koutras, Angelos
    Christodoulou, Christos
    Fountzilas, George
    ANTICANCER RESEARCH, 2021, 41 (04) : 1793 - 1802
  • [35] Management of adverse events in patients with HER2+metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)
    Park-Simon, T. -W
    Okines, A.
    Paplomata, E.
    Wahl, T.
    Wright, G.
    Sutherland, S.
    Jakobsen, E.
    Valdes-Albini, F.
    Chan, A.
    Clark, A. S.
    Conlin, A.
    Lustberg, M.
    Specht, J.
    Pluard, T.
    Zhu, X.
    Krop, I
    Gelmon, K.
    Slamon, D.
    Ramos, J.
    Feng, W.
    Hamilton, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 243 - 244
  • [36] Management of adverse events in patients with HER2+metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).
    Okines, Alicia Frances Clare
    Paplomata, Elisavet
    Wahl, Tanya A.
    Wright, Gail Lynn Shaw
    Sutherland, Stephanie
    Jakobsen, Erik
    Valdes, Frances
    Chan, Arlene
    Clark, Amy Sanders
    Conlin, Alison Katherine
    Lustberg, Maryam B.
    Specht, Jennifer M.
    Pluard, Timothy J.
    Zhu, Xiaofu
    Krop, Ian E.
    Gelmon, Karen A.
    Slamon, Dennis J.
    Ramos, Jorge
    An, Grace
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] THE POTENTIAL IMPACT OF USING CHANGES IN SERUM HER2 LEVELS TO INITIATE THERAPY CHANGE IN HER2+METASTATIC BREAST CANCER
    Noy, K.
    Dejori, M.
    Ghosh, P.
    Suhail, A. M.
    Leitzel, K.
    Lipton, A.
    Carney, W.
    Wittenberg, G.
    VALUE IN HEALTH, 2010, 13 (03) : A40 - A40
  • [38] Radiolabeled trastuzumab biodistribution and serum HER2 levels in HER2-positive metastatic breast cancer patients
    Perik, Patrick J.
    Lub-de Hogge, Marjolijn N.
    Gietema, Jourik A.
    Jager, Piet L.
    Kosterink, Jos G.
    de Korte, Sander A.
    van Veldhuisen, Drik J.
    van der Graaf, Winette T.
    Sieijfer, Drik T.
    de Vries, Elisabeth G.
    ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [39] HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-postive metastatic breast cancer
    Lee, H. J.
    Seo, A. N.
    Kim, E. J.
    Jang, M. H.
    Suh, K. J.
    Ryu, H. S.
    Kim, Y. J.
    Kim, J. H.
    Im, S-A
    Gong, G.
    Park, I. A.
    Jung, K. H.
    Park, S. Y.
    CANCER RESEARCH, 2013, 73
  • [40] HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
    Lee, Hee Jin
    Seo, An Na
    Kim, Eun Joo
    Jang, Min Hye
    Suh, Koung Jin
    Ryu, Han Suk
    Kim, Yu Jung
    Kim, Jee Hyun
    Im, Seock-Ah
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, In Ae
    Park, So Yeon
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (06) : 755 - 766
12345